Motion · S2M-03281 · 14 Sep 2005

Scottish Medicines Consortium - Breast Cancer Drug, Arimidex, Approved Ahead of the Rest of the United Kingdom

Lodged by Dr Jean Turner Standard Motion 13 supporters

The motion

That the Parliament congratulates the Scottish Medicines Consortium (SMC) for backing, ahead of the rest of the United Kingdom, the use in Scotland of the breast cancer drug, anastrazole (Arimidex) for first-line therapy in the adjuvant treatment of postmenopausal women with oestrogen receptor-positive early invasive breast cancer; notes that in trials this drug cut the risk of cancer returning in older woman to less than one in four, and further notes that the backing is ahead of the appraisal by the National Institute for Health and Clinical Excellence (NICE) who may not be appraising this drug until November 2006 due to funding cuts of £3.5 million.

Supporters (13)

Source: the Scottish Parliament motions and amendments record.